Homozygous Familial Hypercholesterolemia Market to Reach New Heights in Growth by 2034, DelveInsight Predicts
DelveInsight's 'Homozygous Familial Hypercholesterolemia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Homozygous Familial Hypercholesterolemia, historical and forecasted epidemiology as well as the Homozygous Familial Hypercholesterolemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Homozygous Familial Hypercholesterolemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Homozygous Familial Hypercholesterolemia Market Forecast
Some of the key facts of the Homozygous Familial Hypercholesterolemia Market Report:
The Homozygous Familial Hypercholesterolemia market size was valued approximately USD 108 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In March 2025, Esperion (NASDAQ: ESPR) has announced that, following discussions with the U.S. Food and Drug Administration (FDA), it has received regulatory alignment to proceed with Phase 3 clinical trials of bempedoic acid—both as a standalone therapy and in combination with ezetimibe—in pediatric patients with heterozygous and homozygous familial hypercholesterolemia (HeFH and HoFH). The company intends to launch these trials later this year. Notably, the FDA has previously granted orphan drug designation to bempedoic acid for the treatment of HoFH.
In January 2025, LIB Therapeutics Inc. (LIB), a privately held, late-stage biopharmaceutical company developing Lerodalcibep—a next-generation PCSK9 inhibitor—announced that results from its Phase 3 LIBerate-HoFH trial have been published in The Lancet Diabetes & Endocrinology (Raal, F.J. et al., 2025). The study evaluated Lerodalcibep in a globally diverse population with homozygous familial hypercholesterolemia (HoFH).
DelveInsight's 2022 analysis indicates that there were approximately 2,845 diagnosed prevalent cases of HoFH in the 7MM. This number is projected to rise significantly by 2034, with a notable CAGR throughout the study period (2020–2034).
Estimates from DelveInsight's epidemiology model suggest that there were around 1,349 diagnosed prevalent cases of HoFH in the US in 2022. This number is projected to increase by 2034 over the study period (2020–2034).
In the 7MM, the EU4 and the UK accounted for about 38% of the total diagnosed prevalent cases of HoFH in 2022, with expectations for this figure to rise further during the study period.
According to DelveInsight's analysis, the United States alone represented approximately 47% of all diagnosed prevalent cases of HoFH among the 7MM in 2022.
Key Homozygous Familial Hypercholesterolemia Companies: Arrowhead Pharmaceutical, Novartis, Alnylam Pharmaceutical, LIB Therapeutics, Amryt Pharma, Novartis, Ultragenyx Pharmaceutical, Arrowhead Pharmaceuticals, Sanofi, Cerenis Therapeutics, Aegerion Pharmaceuticals, The Medicines Company, Akeso, Aegerion Pharmaceuticals, and others
Key Homozygous Familial Hypercholesterolemia Therapies: ARO-ANG3, LEQVIO (inclisiran/KJX839), Lerodalcibep (LIB003), Lomitapide, Inclisiran, Evinacumab, ARO-ANG 3 Injection, Alirocumab, CER-001, lomitapide, ALN-PCSSC, AK102, AEGR-733, and others
The Homozygous Familial Hypercholesterolemia epidemiology based on mutation-specific cases analyzed that a mutation in the LDLR gene accounted for the highest diagnosed prevalent cases in the US
The Homozygous Familial Hypercholesterolemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Homozygous Familial Hypercholesterolemia pipeline products will significantly revolutionize the Homozygous Familial Hypercholesterolemia market dynamics.
Homozygous Familial Hypercholesterolemia Overview
Homozygous Familial Hypercholesterolemia (HoFH) is a rare and severe genetic disorder characterized by extremely high levels of low-density lipoprotein cholesterol (LDL-C) from birth. It is caused by mutations in both alleles of genes involved in the clearance of LDL-C from the bloodstream, typically the LDL receptor gene. This condition leads to early and aggressive atherosclerosis, increasing the risk of heart attacks, strokes, and other cardiovascular diseases at a young age.
Get a Free sample for the Homozygous Familial Hypercholesterolemia Market Forecast, Size & Share Analysis Report:
Homozygous Familial Hypercholesterolemia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Homozygous Familial Hypercholesterolemia Epidemiology Segmentation:
The Homozygous Familial Hypercholesterolemia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Diagnosed Prevalent Cases of HoFH in the 7MM
Mutation-specific Diagnosed Prevalent Cases of HoFHin the 7MM
Download the report to understand which factors are driving Homozygous Familial Hypercholesterolemia epidemiology trends @ Homozygous Familial Hypercholesterolemia Epidemiology Forecast
Homozygous Familial Hypercholesterolemia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Homozygous Familial Hypercholesterolemia market or expected to get launched during the study period. The analysis covers Homozygous Familial Hypercholesterolemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Homozygous Familial Hypercholesterolemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Homozygous Familial Hypercholesterolemia Therapies and Key Companies
Homozygous Familial Hypercholesterolemia Market Strengths
The clarity in disease understanding and pathogenesis has driven the development of novel pharmacological options like PCSK9 inhibitors, ANGPTL3 inhibitors, and MTP inhibitor
Updated international diagnostic and clinical guidelines for FH and HoFH enable evidence-based therapeutic approaches and screening strategies for early identification
Advances in research have led to the discovery of novel molecules like siRNA and recombinant fusion protein that may offer novel options to lower LDL significantly
Homozygous Familial Hypercholesterolemia Market Opportunities
Preclinical studies have yielded gene therapy and CRISPR-based gene editing approaches; conducting further research and clinical trials may offer curative therapy.
Current therapies do not impart sufficient cholesterol-lowering allowing pharma players to bring newer, more potent, and better LDL-C lowering therapies and prevent ASCVD in HoFH patients.
Advancements in healthcare technologies and digital health solutions can potentially enhance early detection and personalized management of HoFH.
Scope of the Homozygous Familial Hypercholesterolemia Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Homozygous Familial Hypercholesterolemia Companies: Arrowhead Pharmaceutical, Novartis, Alnylam Pharmaceutical, LIB Therapeutics, Amryt Pharma, Novartis, Ultragenyx Pharmaceutical, Arrowhead Pharmaceuticals, Sanofi, Cerenis Therapeutics, Aegerion Pharmaceuticals, The Medicines Company, Akeso, Aegerion Pharmaceuticals, and others
Key Homozygous Familial Hypercholesterolemia Therapies: ARO-ANG3, LEQVIO (inclisiran/KJX839), Lerodalcibep (LIB003), Lomitapide, Inclisiran, Evinacumab, ARO-ANG 3 Injection, Alirocumab, CER-001, lomitapide, ALN-PCSSC, AK102, AEGR-733, and others
Homozygous Familial Hypercholesterolemia Therapeutic Assessment: Homozygous Familial Hypercholesterolemia current marketed and Homozygous Familial Hypercholesterolemia emerging therapies
Homozygous Familial Hypercholesterolemia Market Dynamics: Homozygous Familial Hypercholesterolemia market drivers and Homozygous Familial Hypercholesterolemia market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Homozygous Familial Hypercholesterolemia Unmet Needs, KOL's views, Analyst's views, Homozygous Familial Hypercholesterolemia Market Access and Reimbursement
Table of Contents
1. Homozygous Familial Hypercholesterolemia Market Report Introduction
2. Executive Summary for Homozygous Familial Hypercholesterolemia
3. SWOT analysis of Homozygous Familial Hypercholesterolemia
4. Homozygous Familial Hypercholesterolemia Patient Share (%) Overview at a Glance
5. Homozygous Familial Hypercholesterolemia Market Overview at a Glance
6. Homozygous Familial Hypercholesterolemia Disease Background and Overview
7. Homozygous Familial Hypercholesterolemia Epidemiology and Patient Population
8. Country-Specific Patient Population of Homozygous Familial Hypercholesterolemia
9. Homozygous Familial Hypercholesterolemia Current Treatment and Medical Practices
10. Homozygous Familial Hypercholesterolemia Unmet Needs
11. Homozygous Familial Hypercholesterolemia Emerging Therapies
12. Homozygous Familial Hypercholesterolemia Market Outlook
13. Country-Wise Homozygous Familial Hypercholesterolemia Market Analysis (2020–2034)
14. Homozygous Familial Hypercholesterolemia Market Access and Reimbursement of Therapies
15. Homozygous Familial Hypercholesterolemia Market Drivers
16. Homozygous Familial Hypercholesterolemia Market Barriers
17. Homozygous Familial Hypercholesterolemia Appendix
18. Homozygous Familial Hypercholesterolemia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
an hour ago
- CTV News
Tesla's six-seat Model Y variant may not be launched in U.S.
Tesla CEO Elon Musk said the company's new six-seat Model Y variant, launched in China this week, might never enter production in the United States, citing the rise of self-driving vehicles. The Model Y L, built at Tesla's Shanghai factory, features a longer wheelbase and three rows of seats, and is priced at around US$47,200. It went on sale in China on Tuesday, where Tesla faces mounting competition from domestic EV makers such as BYD and Xiaomi. 'This variant of the Model Y doesn't start production in the US until the end of next year,' Musk said in a response to a post from an X user. 'Might not ever, given the advent of self-driving in America.' Musk did not elaborate on how the rise of autonomous driving would negate the need for a six-seater vehicle. Tesla did not immediately respond to a request for comment. Gas-powered SUVs with three rows have long been popular among American families. However, making profitable three-row EVs is still a challenging business for automakers. Recent policy changes by the Trump administration are also set to make electric vehicles more expensive, prompting automakers to focus more on smaller, cheaper variants. Tesla is also preparing to launch a cheaper Model Y variant, likely with fewer premium features, later this year, which Musk has described as 'just a Model Y.' Tesla has increasingly shifted focus in the U.S. to its robotaxi ambitions. The company launched a limited robotaxi service in Austin in June and aims to scale operations to half of U.S. population by the end of this year. Musk told investors last year that building traditional vehicles would be 'pointless' in a self-driving future. Next year, Tesla is set to start production of the Cybercab, a dedicated two-seater robotaxi model without a steering wheel and pedals. (Reporting by Akash Sriram in Bengaluru and Abhirup Roy in San Francisco; Editing by Anil D'Silva)
Global News
3 hours ago
- Global News
Nearly 20% of Canadian small businesses may close from tariffs, CFIB says
Nearly 20 per cent of Canadian small businesses are at risk of having to shut down in as little as six months as owners grapple with higher costs brought on by tariffs, new data suggests. 'Small businesses don't have a lot of runway left. They are trying their best to absorb the costs, but if nothing changes, they will be forced to make some tough decisions,' said Corinne Pohlmann, executive vice-president at the Canadian Federation of Independent Business (CFIB). 'The worst outcome for Canada in the trade war is a bad deal, but the second-worst outcome is the never-ending uncertainty small business owners have been wrestling with for the past six months.' According to the CFIB, nearly one in five (19 per cent) of small business owners report they won't last more than six months if the tariff status quo remains, and nearly four in 10 (38 per cent) said they would last less than a year. Story continues below advertisement United States President Donald Trump sparked a trade war earlier this year by imposing tariff policies on virtually all countries, including Canada, which also led to counter-tariff measures. Although many goods listed under the current trade agreement, known as the Canada-United States-Mexico Agreement (CUSMA), are exempt from most tariffs, there are still many goods that businesses have to pay more for due to these new tariffs. Other trade tensions between Canada and China have also meant higher costs for some sectors, including the Canadian canola industry. 2:06 Canola farmers brace for China's 'devastating' tariffs One of the ways businesses are staying afloat is by 'absorbing' the higher costs from tariffs, as noted by the Bank of Canada in July following the release of its latest survey of business and consumer sentiments. Story continues below advertisement 'Tariff-related cost increases are also putting upward pressure on firms' expected selling prices,' the Bank of Canada said in its survey summary. Get breaking National news For news impacting Canada and around the world, sign up for breaking news alerts delivered directly to you when they happen. Sign up for breaking National newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy 'Because customers are sensitive to price increases, many firms are absorbing a portion of these increased costs, compressing their profit margins in an effort to preserve market share.' The data from the CFIB suggests that may not be an option for much longer. 'There is a breaking point, and I think we're coming to that breaking point where some of them (small business owners) are saying, 'I just can't continue to absorb this and stay competitive — it's just becoming too difficult,'' Pohlmann says. 'In the meantime, some are temporarily laying people off because they just don't have the work, or they're just trying to find other ways to address the expenses that are coming their way, and of course many are increasing prices to do that.' 1:07 Retaliatory tariffs should have 'minimum impact' on Canadians, Carney says The federal government will be releasing its fall budget soon, which is expected to include billions in new spending aimed at bolstering the Canadian economy amid the trade war. Story continues below advertisement The focus of these spending promises has been mainly on the housing, industry and energy sectors, but there hasn't been as much clarity on supports specific to small business owners. 'There's many different suggestions we're making to the government on how they can do this. It could be something along the lines of a rebate to many small businesses impacted. Another could be to lower certain taxes even temporarily in order for them to have a bit more to keep in their business for now rather than have to pay to government,' Pohlmann says. 'There's lots of different ways that they could find to help those small businesses potentially keep some of that cash within their business and hopefully help them last a bit longer.'
Globe and Mail
5 hours ago
- Globe and Mail
Oconee Federal Financial Corp. Announces Annual Financial Results
Oconee Federal Financial Corp. (OTCQX: OFED) (the 'Company'), the holding company for Oconee Federal Savings and Loan Association ('Oconee Federal'), announced today net income of $4.2 million, or $0.73 per diluted share, for the year ended June 30, 2025, compared to the net income of $6.3 million, or $1.10 per diluted share, for the year ended June 30, 2024. June 30, 2025 Year End Summary: Fifty-five consecutive quarterly dividends of $0.10 per share since the quarter ended December 2011. Total assets were $668.2 million, an increase of 0.39% from $665.6 million at June 30, 2024. Total loans outstanding were $478.7 million, up from $469.7 million at June 30, 2024. 'The year ended June 30, 2025 was a good year for Oconee Federal. With our increased size since our acquisition of Mutual Savings Bank in Hartsville, SC in January 2024, along with the current interest rate environment, our net interest margin has improved from $12.1 million for the year ended June 30, 2024 to $15.5 million for the year ended June 30, 2025,' stated Curtis T. Evatt, President and Chief Executive Officer. 'Net of the prior year bargain purchase gain of $4.9 million, our net income has improved from $1.4 million for the year ended June 30, 2024 to $4.2 million for the year ended June 30, 2025. Our capital ratios continue to be among some of the highest in the industry. We are looking forward to the opportunity of providing the best products and services to our customers in the coming year.' Cash Dividend Declared Total dividends paid during the year ended June 30, 2025 were $2.3 million. On July 23, 2025, the Board of Directors of the Company declared a quarterly cash dividend of $0.10 per share of the Company's common stock payable to stockholders of record as of August 7, 2025, which is payable on August 21, 2025. About Oconee Federal Oconee Federal Financial Corp. (OTCQX: OFED) is the holding company of Oconee Federal Savings and Loan Association. Oconee Federal Savings and Loan Association is a federally chartered savings and loan association founded in 1924 and headquartered in Seneca, South Carolina. Oconee Federal Savings and Loan Association is a community oriented financial institution operating eight full-service branch locations in Oconee County, South Carolina, Pickens County, South Carolina, Darlington County, South Carolina, Stephens County, Georgia and Rabun County, Georgia. For future financial information, please access our investor information page on our website at Forward-Looking Statements This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on current expectations, estimates and projections about the Company's and the Association's industry, and management's beliefs and assumptions. Words such as anticipates, expects, intends, plans, believes, estimates and variations of such words and expressions are intended to identify fiscal year forward-looking statements. Such statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to forecast. Therefore, actual results may differ materially from those expressed or forecast in such forward-looking statements. The Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information or otherwise.
